Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyMagnesium salicylate
Identification
- Name
- Magnesium salicylate
- Accession Number
- DB01397
- Type
- Small Molecule
- Groups
- Approved
- Description
Magnesium salicylate is a common analgesic and non-steroidal anti-inflammatory drug (NSAID) used to treat mild to moderate muscular pain. It is also used to treat headaches, general back pain, and certain joint pains like arthritis.
It is found in a variety of over-the-counter (OTC) medications as an anti-inflammatory, primarily for back-pain relief. Magnesium Salicylate can be an effective OTC alternative to prescription NSAIDs, with both anti-inflamatory and pain-relieving effects.
Though the recommended doseage is 1160 mg every six hours, per package directions of the Doan's OTC brand (580 mg magnesium salicylate tetrahydrate, equivalent to 934.4 mg anhydrous magnesium salicylate), effective pain relief is often found with a half dosage, with reduced anti-inflammatory results.
- Structure
Structure for DB01397 (Magnesium salicylate)
- Synonyms
- Magnesium salicylate anhydrous
- Product Ingredients
Ingredient UNII CAS InChI Key Magnesium salicylate tetrahydrate 41728CY7UX 18917-95-8 CWQGWAKCTBFURY-UHFFFAOYSA-J - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Arthriten Tablets Tablet 325 mg Oral Alva Amco Pharmacal Companies, Inc. 2003-05-15 2006-07-27 Canada 
Back-ese M Tab 325mg Tablet 325 mg Oral G.T. Fulford Pharmaceuticals 1985-12-31 1998-06-25 Canada Back-ese M Tablets 325 mg Tablet 325 mg Oral Dannorth Laboratories Inc. 1980-12-31 2000-07-19 Canada Backache Aid Tablet, film coated 580 mg/1 Oral L&R Distributors, Inc. 1998-11-07 Not applicable US 
Backache Relief Tablet, film coated 580 mg/1 Oral CVS Health 1998-11-07 Not applicable US Backache Relief Tablet, film coated 580 mg/1 Oral Rite Aid 1998-11-07 Not applicable US Backache Relief Extra Strength Tablet 580 mg/1 Oral Walgreen 1998-11-07 2018-04-10 US Backache Relief Extra Strength Tablet, film coated 580 mg/1 Oral Lnk International, Inc. 1998-11-07 Not applicable US Doan's Backache Pills 325mg Tablet 325 mg Oral Novartis 1988-12-31 1998-07-08 Canada Doans Extra Strength Tablet 580 mg/1 Oral Dr Reddy's Laboratories 2013-05-15 Not applicable US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Back Relief Magnesium salicylate (200 mg/1) + Acetaminophen (200 mg/1) Tablet Oral North Safety Products 2017-12-20 Not applicable US Back Relief Magnesium salicylate (200 mg/1) + Acetaminophen (200 mg/1) Tablet Oral North Safety Products 2013-05-14 2018-01-06 US Diurex Water Pills Magnesium salicylate (162.5 mg/1) + Caffeine (50 mg/1) Tablet, coated Oral Alva Amco Pharmacal Companies, Inc. 2005-05-15 Not applicable US MEDIQUE Back Pain Off Magnesium salicylate (290 mg/1) + Acetaminophen (250 mg/1) + Caffeine (50 mg/1) Tablet, film coated Oral Unifirst First Aid 2008-12-30 Not applicable US Otis Clapp Back Quell Magnesium salicylate (200 mg/1) + Acetaminophen (200 mg/1) Tablet, film coated Oral Unifirst First Aid 2008-12-30 Not applicable US Pain Aid BRF Magnesium salicylate (250 mg/1) + Acetaminophen (250 mg/1) Tablet Oral Zee Medical Inc 2012-08-19 Not applicable US Pamprin Cramp Menstrual Pain Relief Magnesium salicylate (250 mg/1) + Acetaminophen (250 mg/1) Tablet Oral Chattem, Inc. 1983-01-01 Not applicable US Trilisate Tab Magnesium salicylate (362 mg) + Choline salicylate (293 mg) Tablet Oral Purdue Pharma 1979-12-31 2002-07-30 Canada Vica-cet Magnesium salicylate (250 mg/1) + Acetaminophen (250 mg/1) Tablet Oral Provision Medical 2015-04-03 Not applicable US - Categories
- Acids, Carbocyclic
- Analgesics
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Anti-Inflammatory Agents, Non-Steroidal (Non-Selective)
- Benzene Derivatives
- Benzoates
- Central Nervous System Agents
- COX Inhibitors
- COX-1 Inhibitors
- COX-2 Inhibitors
- Cyclooxygenase Inhibitors
- Enzyme Inhibitors
- Hydroxy Acids
- Hydroxybenzoates
- Magnesium Salts
- Nephrotoxic agents
- Peripheral Nervous System Agents
- Phenols
- Sensory System Agents
- UNII
- JQ69D454N1
- CAS number
- 18917-89-0
- Weight
- Average: 298.531
Monoisotopic: 298.03277995 - Chemical Formula
- C14H10MgO6
- InChI Key
- MQHWFIOJQSCFNM-UHFFFAOYSA-L
- InChI
- InChI=1S/2C7H6O3.Mg/c2*8-6-4-2-1-3-5(6)7(9)10;/h2*1-4,8H,(H,9,10);/q;;+2/p-2
- IUPAC Name
- magnesium(2+) ion bis(2-hydroxybenzoate)
- SMILES
- [Mg++].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O
Pharmacology
- Indication
Magnesium salicylate is a common analgesic and non-steroidal anti-inflammatory drug (NSAID) used to treat mild to moderate muscular pain
- Pharmacodynamics
- Not Available
- Mechanism of action
Most NSAIDs act as nonselective inhibitors of the enzyme cyclooxygenase (COX), inhibiting both the cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) isoenzymes. COX catalyzes the formation of prostaglandins and thromboxane from arachidonic acid (itself derived from the cellular phospholipid bilayer by phospholipase A2). Prostaglandins act (among other things) as messenger molecules in the process of inflammation.
Target Actions Organism AProstaglandin G/H synthase 2 inhibitorHuman AProstaglandin G/H synthase 1 inhibitorHuman - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
Pathway Category Magnesium salicylate Action Pathway Drug action Magnesium salicylate Action Pathway Drug action - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (4R)-limonene The risk or severity of adverse effects can be increased when (4R)-limonene is combined with Magnesium salicylate. Investigational 16-Bromoepiandrosterone The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with 16-Bromoepiandrosterone. Investigational 19-norandrostenedione The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with 19-norandrostenedione. Experimental, Illicit 5-androstenedione The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with 5-androstenedione. Experimental, Illicit Abciximab Magnesium salicylate may increase the anticoagulant activities of Abciximab. Approved Acebutolol Magnesium salicylate may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Aceclofenac The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Aceclofenac. Approved, Investigational Acemetacin The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Acemetacin. Approved, Experimental, Investigational Acenocoumarol Magnesium salicylate may increase the anticoagulant activities of Acenocoumarol. Approved, Investigational Adapalene The risk or severity of adverse effects can be increased when Adapalene is combined with Magnesium salicylate. Approved Agmatine The risk or severity of hypotension and neuromuscular blockade can be increased when Agmatine is combined with Magnesium salicylate. Experimental, Investigational Alaproclate Alaproclate may increase the antiplatelet activities of Magnesium salicylate. Experimental Alclofenac The risk or severity of adverse effects can be increased when Alclofenac is combined with Magnesium salicylate. Approved, Withdrawn Alclometasone The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Alclometasone. Approved Alcuronium Magnesium salicylate may increase the neuromuscular blocking activities of Alcuronium. Experimental Aldosterone The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Aldosterone. Experimental, Investigational Alendronic acid The serum concentration of Alendronic acid can be decreased when it is combined with Magnesium salicylate. Approved Alfacalcidol The serum concentration of Magnesium salicylate can be increased when it is combined with Alfacalcidol. Approved, Nutraceutical Aliskiren Magnesium salicylate may decrease the antihypertensive activities of Aliskiren. Approved, Investigational Alminoprofen The risk or severity of adverse effects can be increased when Alminoprofen is combined with Magnesium salicylate. Experimental Alprenolol Magnesium salicylate may decrease the antihypertensive activities of Alprenolol. Approved, Withdrawn Alprostadil The therapeutic efficacy of Alprostadil can be decreased when used in combination with Magnesium salicylate. Approved, Investigational Amcinonide The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Amcinonide. Approved Amikacin The risk or severity of nephrotoxicity can be increased when Magnesium salicylate is combined with Amikacin. Approved, Investigational, Vet Approved Amiloride Magnesium salicylate may decrease the antihypertensive activities of Amiloride. Approved Aminosalicylic Acid The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Aminosalicylic Acid. Approved Amiodarone The risk or severity of hypotension and neuromuscular blockade can be increased when Amiodarone is combined with Magnesium salicylate. Approved, Investigational Amlodipine The risk or severity of hypotension and neuromuscular blockade can be increased when Amlodipine is combined with Magnesium salicylate. Approved Amrinone The risk or severity of hypotension and neuromuscular blockade can be increased when Amrinone is combined with Magnesium salicylate. Approved Ancrod Magnesium salicylate may increase the anticoagulant activities of Ancrod. Approved, Investigational Andrographolide The risk or severity of adverse effects can be increased when Andrographolide is combined with Magnesium salicylate. Investigational Androstenedione The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Androstenedione. Experimental, Illicit Anecortave The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Anecortave. Investigational anecortave acetate The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with anecortave acetate. Investigational Anisodamine The risk or severity of adverse effects can be increased when Anisodamine is combined with Magnesium salicylate. Investigational Antipyrine The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Antipyrine. Approved, Investigational Antithrombin III human Magnesium salicylate may increase the anticoagulant activities of Antithrombin III human. Approved Antrafenine The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Antrafenine. Approved Apixaban Magnesium salicylate may increase the anticoagulant activities of Apixaban. Approved Apocynin The risk or severity of adverse effects can be increased when Apocynin is combined with Magnesium salicylate. Investigational Apramycin Magnesium salicylate may decrease the excretion rate of Apramycin which could result in a higher serum level. Experimental, Vet Approved Apremilast The risk or severity of adverse effects can be increased when Apremilast is combined with Magnesium salicylate. Approved, Investigational Aranidipine The risk or severity of hypotension and neuromuscular blockade can be increased when Aranidipine is combined with Magnesium salicylate. Approved, Investigational Arbekacin Magnesium salicylate may decrease the excretion rate of Arbekacin which could result in a higher serum level. Approved, Investigational Ardeparin Magnesium salicylate may increase the anticoagulant activities of Ardeparin. Approved, Investigational, Withdrawn Argatroban Magnesium salicylate may increase the anticoagulant activities of Argatroban. Approved, Investigational Arotinolol Magnesium salicylate may decrease the antihypertensive activities of Arotinolol. Investigational Asenapine Magnesium salicylate may decrease the antihypertensive activities of Asenapine. Approved Atamestane The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Atamestane. Investigational Atenolol Magnesium salicylate may decrease the antihypertensive activities of Atenolol. Approved Atracurium Magnesium salicylate may increase the neuromuscular blocking activities of Atracurium. Approved, Experimental, Investigational Atracurium besylate Magnesium salicylate may increase the neuromuscular blocking activities of Atracurium besylate. Approved Azapropazone The risk or severity of adverse effects can be increased when Azapropazone is combined with Magnesium salicylate. Withdrawn Azelastine The risk or severity of adverse effects can be increased when Azelastine is combined with Magnesium salicylate. Approved Azelnidipine The risk or severity of hypotension and neuromuscular blockade can be increased when Azelnidipine is combined with Magnesium salicylate. Approved, Investigational Azficel-T The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Azficel-T. Approved, Investigational Azilsartan medoxomil The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Magnesium salicylate. Approved, Investigational Azimilide The risk or severity of hypotension and neuromuscular blockade can be increased when Azimilide is combined with Magnesium salicylate. Investigational Azosemide The therapeutic efficacy of Azosemide can be decreased when used in combination with Magnesium salicylate. Investigational Bacitracin The risk or severity of nephrotoxicity can be increased when Magnesium salicylate is combined with Bacitracin. Approved, Vet Approved Balsalazide The risk or severity of adverse effects can be increased when Balsalazide is combined with Magnesium salicylate. Approved, Investigational Barnidipine The risk or severity of hypotension and neuromuscular blockade can be increased when Barnidipine is combined with Magnesium salicylate. Approved Bazedoxifene Magnesium salicylate may increase the thrombogenic activities of Bazedoxifene. Approved, Investigational Becaplermin Magnesium salicylate may increase the anticoagulant activities of Becaplermin. Approved, Investigational Beclomethasone dipropionate The risk or severity of gastrointestinal irritation can be increased when Beclomethasone dipropionate is combined with Magnesium salicylate. Approved, Investigational Befunolol Magnesium salicylate may decrease the antihypertensive activities of Befunolol. Experimental Bekanamycin Magnesium salicylate may decrease the excretion rate of Bekanamycin which could result in a higher serum level. Experimental Benazepril The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Benazepril. Approved, Investigational Bencyclane The risk or severity of hypotension and neuromuscular blockade can be increased when Bencyclane is combined with Magnesium salicylate. Experimental Bendazac The risk or severity of adverse effects can be increased when Bendazac is combined with Magnesium salicylate. Experimental Bendroflumethiazide The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Magnesium salicylate. Approved Benidipine The risk or severity of hypotension and neuromuscular blockade can be increased when Benidipine is combined with Magnesium salicylate. Approved, Investigational Benorilate The risk or severity of adverse effects can be increased when Benorilate is combined with Magnesium salicylate. Experimental Benoxaprofen The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Magnesium salicylate. Withdrawn Benzthiazide The therapeutic efficacy of Benzthiazide can be decreased when used in combination with Magnesium salicylate. Approved Benzydamine The risk or severity of adverse effects can be increased when Benzydamine is combined with Magnesium salicylate. Approved Bepridil The risk or severity of hypotension and neuromuscular blockade can be increased when Bepridil is combined with Magnesium salicylate. Approved, Withdrawn Beraprost The therapeutic efficacy of Beraprost can be decreased when used in combination with Magnesium salicylate. Investigational Betamethasone The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Betamethasone. Approved, Vet Approved Betaxolol Magnesium salicylate may decrease the antihypertensive activities of Betaxolol. Approved, Investigational Betrixaban The risk or severity of bleeding can be increased when Betrixaban is combined with Magnesium salicylate. Approved, Investigational Bevantolol Magnesium salicylate may decrease the antihypertensive activities of Bevantolol. Approved Bevonium The risk or severity of adverse effects can be increased when Bevonium is combined with Magnesium salicylate. Experimental Bimatoprost The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Magnesium salicylate. Approved, Investigational Bioallethrin The risk or severity of hypotension and neuromuscular blockade can be increased when Bioallethrin is combined with Magnesium salicylate. Approved, Experimental Bisoprolol Magnesium salicylate may decrease the antihypertensive activities of Bisoprolol. Approved Bivalirudin Magnesium salicylate may increase the anticoagulant activities of Bivalirudin. Approved, Investigational Bopindolol Magnesium salicylate may decrease the antihypertensive activities of Bopindolol. Approved Bromfenac The risk or severity of adverse effects can be increased when Bromfenac is combined with Magnesium salicylate. Approved Bucillamine The risk or severity of adverse effects can be increased when Bucillamine is combined with Magnesium salicylate. Investigational Bucindolol Magnesium salicylate may decrease the antihypertensive activities of Bucindolol. Investigational Budesonide The risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Magnesium salicylate. Approved Bufexamac The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Bufexamac. Approved, Experimental Bufuralol Magnesium salicylate may decrease the antihypertensive activities of Bufuralol. Experimental, Investigational Bumadizone The risk or severity of adverse effects can be increased when Bumadizone is combined with Magnesium salicylate. Experimental Bumetanide The therapeutic efficacy of Bumetanide can be decreased when used in combination with Magnesium salicylate. Approved Bupranolol Magnesium salicylate may decrease the antihypertensive activities of Bupranolol. Approved Calcitriol The serum concentration of Magnesium salicylate can be increased when it is combined with Calcitriol. Approved, Nutraceutical Candesartan The risk or severity of adverse effects can be increased when Candesartan is combined with Magnesium salicylate. Experimental Candesartan cilexetil The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Magnesium salicylate. Approved Candoxatril The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Candoxatril. Experimental Capsaicin The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Capsaicin. Approved Captopril The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Captopril. Approved Carbaspirin calcium The risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Magnesium salicylate. Experimental, Investigational Carboprost Tromethamine The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Magnesium salicylate. Approved Carboxyamidotriazole The risk or severity of hypotension and neuromuscular blockade can be increased when Carboxyamidotriazole is combined with Magnesium salicylate. Investigational Caroverine The risk or severity of hypotension and neuromuscular blockade can be increased when Caroverine is combined with Magnesium salicylate. Experimental Carprofen The risk or severity of adverse effects can be increased when Carprofen is combined with Magnesium salicylate. Approved, Vet Approved, Withdrawn Carteolol Magnesium salicylate may decrease the antihypertensive activities of Carteolol. Approved Carvedilol Magnesium salicylate may decrease the antihypertensive activities of Carvedilol. Approved, Investigational Castanospermine The risk or severity of adverse effects can be increased when Castanospermine is combined with Magnesium salicylate. Experimental Celecoxib The risk or severity of adverse effects can be increased when Celecoxib is combined with Magnesium salicylate. Approved, Investigational Celiprolol Magnesium salicylate may decrease the antihypertensive activities of Celiprolol. Approved, Investigational Certoparin Magnesium salicylate may increase the anticoagulant activities of Certoparin. Approved, Investigational Chloroquine The risk or severity of adverse effects can be increased when Chloroquine is combined with Magnesium salicylate. Approved, Investigational, Vet Approved Chlorothiazide The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Magnesium salicylate. Approved, Vet Approved Chlorotrianisene Magnesium salicylate may increase the thrombogenic activities of Chlorotrianisene. Investigational, Withdrawn Chlorphenesin The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Chlorphenesin. Approved, Vet Approved, Withdrawn Chlortetracycline Magnesium salicylate can cause a decrease in the absorption of Chlortetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational, Vet Approved Chlorthalidone The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Magnesium salicylate. Approved Cholestyramine Cholestyramine can cause a decrease in the absorption of Magnesium salicylate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Choline magnesium trisalicylate The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Choline magnesium trisalicylate. Approved Ciclesonide The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Ciclesonide. Approved, Investigational Cilazapril The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Cilazapril. Approved Cilnidipine The risk or severity of hypotension and neuromuscular blockade can be increased when Cilnidipine is combined with Magnesium salicylate. Approved, Investigational Cimicoxib The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Cimicoxib. Investigational Cinnarizine The risk or severity of hypotension and neuromuscular blockade can be increased when Cinnarizine is combined with Magnesium salicylate. Approved, Investigational Cinoxacin The serum concentration of Cinoxacin can be decreased when it is combined with Magnesium salicylate. Approved, Investigational, Withdrawn Ciprofloxacin Magnesium salicylate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Cisatracurium Magnesium salicylate may increase the neuromuscular blocking activities of Cisatracurium. Approved Cisplatin The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Cisplatin. Approved Citalopram Citalopram may increase the antiplatelet activities of Magnesium salicylate. Approved Clevidipine The risk or severity of hypotension and neuromuscular blockade can be increased when Clevidipine is combined with Magnesium salicylate. Approved, Investigational Clobetasol The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Clobetasol. Approved, Investigational Clobetasol propionate The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Clobetasol propionate. Approved Clobetasone The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Clobetasone. Approved Clocortolone The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Clocortolone. Approved Clodronic Acid The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Clodronic Acid. Approved, Investigational, Vet Approved Clonixin The risk or severity of adverse effects can be increased when Clonixin is combined with Magnesium salicylate. Approved Cloprostenol The therapeutic efficacy of Cloprostenol can be decreased when used in combination with Magnesium salicylate. Vet Approved Cloranolol Magnesium salicylate may decrease the antihypertensive activities of Cloranolol. Experimental Clorindione Magnesium salicylate may increase the anticoagulant activities of Clorindione. Experimental Colesevelam Colesevelam can cause a decrease in the absorption of Magnesium salicylate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Colestipol Colestipol can cause a decrease in the absorption of Magnesium salicylate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Conjugated estrogens Magnesium salicylate may increase the thrombogenic activities of Conjugated estrogens. Approved Cortexolone 17α-propionate The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Cortexolone 17α-propionate. Investigational Corticosterone The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Corticosterone. Experimental Cortisone acetate The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Cortisone acetate. Approved, Investigational Curcumin The risk or severity of adverse effects can be increased when Curcumin is combined with Magnesium salicylate. Approved, Investigational Cyclandelate The risk or severity of hypotension and neuromuscular blockade can be increased when Cyclandelate is combined with Magnesium salicylate. Approved Cyclopenthiazide The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Magnesium salicylate. Experimental Cyclosporine The risk or severity of renal failure and hypertension can be increased when Magnesium salicylate is combined with Cyclosporine. Approved, Investigational, Vet Approved Dabigatran etexilate Magnesium salicylate may increase the anticoagulant activities of Dabigatran etexilate. Approved Daidzein Magnesium salicylate may increase the thrombogenic activities of Daidzein. Experimental Dalteparin Magnesium salicylate may increase the anticoagulant activities of Dalteparin. Approved Danaparoid Magnesium salicylate may increase the anticoagulant activities of Danaparoid. Approved, Withdrawn Dapoxetine Dapoxetine may increase the antiplatelet activities of Magnesium salicylate. Investigational Darexaban Magnesium salicylate may increase the anticoagulant activities of Darexaban. Investigational Darodipine The risk or severity of hypotension and neuromuscular blockade can be increased when Darodipine is combined with Magnesium salicylate. Experimental Decamethonium Magnesium salicylate may increase the neuromuscular blocking activities of Decamethonium. Approved Deferasirox The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Deferasirox. Approved, Investigational Deferiprone The serum concentration of Deferiprone can be decreased when it is combined with Magnesium salicylate. Approved Deflazacort The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Deflazacort. Approved, Investigational Delapril The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Delapril. Investigational Demeclocycline Magnesium salicylate can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Desipramine Magnesium salicylate may decrease the antihypertensive activities of Desipramine. Approved, Investigational Desirudin Magnesium salicylate may increase the anticoagulant activities of Desirudin. Approved Desmopressin The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Desmopressin. Approved Desonide The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Desonide. Approved, Investigational Desoximetasone The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Desoximetasone. Approved Desoxycorticosterone acetate The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Desoxycorticosterone acetate. Approved Desoxycorticosterone Pivalate The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Desoxycorticosterone Pivalate. Experimental, Vet Approved Desvenlafaxine Desvenlafaxine may increase the antiplatelet activities of Magnesium salicylate. Approved, Investigational Dexamethasone The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Magnesium salicylate. Approved, Investigational, Vet Approved Dexamethasone isonicotinate The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Dexamethasone isonicotinate. Vet Approved Dexibuprofen The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Dexibuprofen. Approved, Investigational Dexketoprofen The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Magnesium salicylate. Approved, Investigational Dexniguldipine The risk or severity of hypotension and neuromuscular blockade can be increased when Dexniguldipine is combined with Magnesium salicylate. Experimental Dextran Magnesium salicylate may increase the anticoagulant activities of Dextran. Approved, Investigational, Vet Approved Dexverapamil The risk or severity of hypotension and neuromuscular blockade can be increased when Dexverapamil is combined with Magnesium salicylate. Experimental Dibekacin Magnesium salicylate may decrease the excretion rate of Dibekacin which could result in a higher serum level. Experimental Dibotermin alfa The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Dibotermin alfa. Approved, Investigational Diclofenac The risk or severity of adverse effects can be increased when Diclofenac is combined with Magnesium salicylate. Approved, Vet Approved Dicoumarol Magnesium salicylate may increase the anticoagulant activities of Dicoumarol. Approved Dienestrol Magnesium salicylate may increase the thrombogenic activities of Dienestrol. Approved, Investigational Diethylstilbestrol Magnesium salicylate may increase the thrombogenic activities of Diethylstilbestrol. Approved, Investigational Difenpiramide The risk or severity of adverse effects can be increased when Difenpiramide is combined with Magnesium salicylate. Experimental Diflorasone The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Diflorasone. Approved Diflunisal The risk or severity of adverse effects can be increased when Diflunisal is combined with Magnesium salicylate. Approved, Investigational Difluocortolone The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Difluocortolone. Approved, Investigational, Withdrawn Difluprednate The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Difluprednate. Approved Digoxin The serum concentration of Digoxin can be increased when it is combined with Magnesium salicylate. Approved Dihydrostreptomycin Magnesium salicylate may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level. Investigational, Vet Approved Diltiazem The risk or severity of hypotension and neuromuscular blockade can be increased when Diltiazem is combined with Magnesium salicylate. Approved, Investigational Dinoprost The therapeutic efficacy of Dinoprost can be decreased when used in combination with Magnesium salicylate. Investigational Dinoprost Tromethamine The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Magnesium salicylate. Approved, Vet Approved Dinoprostone The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Magnesium salicylate. Approved Diphenadione Magnesium salicylate may increase the anticoagulant activities of Diphenadione. Experimental Dipotassium phosphate The serum concentration of Dipotassium phosphate can be decreased when it is combined with Magnesium salicylate. Approved Dolutegravir The serum concentration of Dolutegravir can be decreased when it is combined with Magnesium salicylate. Approved Domoic Acid Magnesium salicylate may increase the neuromuscular blocking activities of Domoic Acid. Experimental Dotarizine The risk or severity of hypotension and neuromuscular blockade can be increased when Dotarizine is combined with Magnesium salicylate. Investigational Doxacurium Magnesium salicylate may increase the neuromuscular blocking activities of Doxacurium chloride. Approved Doxazosin The therapeutic efficacy of Doxazosin can be decreased when used in combination with Magnesium salicylate. Approved Doxycycline Magnesium salicylate can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational, Vet Approved Drospirenone Magnesium salicylate may increase the hyperkalemic activities of Drospirenone. Approved Droxicam The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Droxicam. Withdrawn Duloxetine Duloxetine may increase the antiplatelet activities of Magnesium salicylate. Approved Duvelisib The risk or severity of adverse effects can be increased when Duvelisib is combined with Magnesium salicylate. Investigational E-6201 The risk or severity of adverse effects can be increased when E-6201 is combined with Magnesium salicylate. Investigational Edetic Acid Magnesium salicylate may increase the anticoagulant activities of Edetic Acid. Approved, Vet Approved Edoxaban Magnesium salicylate may increase the anticoagulant activities of Edoxaban. Approved Efonidipine The risk or severity of hypotension and neuromuscular blockade can be increased when Efonidipine is combined with Magnesium salicylate. Approved, Investigational Eltrombopag The serum concentration of Eltrombopag can be decreased when it is combined with Magnesium salicylate. Approved Emopamil The risk or severity of hypotension and neuromuscular blockade can be increased when Emopamil is combined with Magnesium salicylate. Experimental Enalapril The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Enalapril. Approved, Vet Approved Enalaprilat The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Enalaprilat. Approved Enoxacin The serum concentration of Enoxacin can be decreased when it is combined with Magnesium salicylate. Approved, Investigational Enoxaparin Magnesium salicylate may increase the anticoagulant activities of Enoxaparin. Approved Enprostil The therapeutic efficacy of Enprostil can be decreased when used in combination with Magnesium salicylate. Experimental Epanolol Magnesium salicylate may decrease the antihypertensive activities of Epanolol. Experimental Eperisone The risk or severity of hypotension and neuromuscular blockade can be increased when Eperisone is combined with Magnesium salicylate. Approved, Investigational Epimestrol Magnesium salicylate may increase the thrombogenic activities of Epimestrol. Experimental Epirizole The risk or severity of adverse effects can be increased when Epirizole is combined with Magnesium salicylate. Approved Epitizide The therapeutic efficacy of Epitizide can be decreased when used in combination with Magnesium salicylate. Experimental Eplerenone Magnesium salicylate may decrease the antihypertensive activities of Eplerenone. Approved Epoprostenol The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Magnesium salicylate. Approved Eprosartan The risk or severity of adverse effects can be increased when Eprosartan is combined with Magnesium salicylate. Approved Equilenin The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Equilenin. Experimental Equilin The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Equilin. Approved Equol Magnesium salicylate may increase the thrombogenic activities of Equol. Investigational Esatenolol Magnesium salicylate may decrease the antihypertensive activities of Esatenolol. Experimental Escitalopram Escitalopram may increase the antiplatelet activities of Magnesium salicylate. Approved, Investigational Esmolol Magnesium salicylate may decrease the antihypertensive activities of Esmolol. Approved Estradiol acetate Magnesium salicylate may increase the thrombogenic activities of Estradiol acetate. Approved, Investigational, Vet Approved Estradiol cypionate Magnesium salicylate may increase the thrombogenic activities of Estradiol cypionate. Approved, Investigational, Vet Approved Estradiol valerate Magnesium salicylate may increase the thrombogenic activities of Estradiol valerate. Approved, Investigational, Vet Approved Estriol Magnesium salicylate may increase the thrombogenic activities of Estriol. Approved, Investigational, Vet Approved Estrogens, esterified Magnesium salicylate may increase the thrombogenic activities of Estrogens, esterified. Approved Estrone The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Estrone. Approved Estrone sulfate The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Estrone sulfate. Approved Etacrynic acid The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Magnesium salicylate. Approved, Investigational Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Magnesium salicylate. Approved, Investigational Ethenzamide The risk or severity of adverse effects can be increased when Ethenzamide is combined with Magnesium salicylate. Experimental Ethosuximide The risk or severity of hypotension and neuromuscular blockade can be increased when Ethosuximide is combined with Magnesium salicylate. Approved Ethyl biscoumacetate Magnesium salicylate may increase the anticoagulant activities of Ethyl biscoumacetate. Withdrawn Etidronic acid The serum concentration of Etidronic acid can be decreased when it is combined with Magnesium salicylate. Approved Etodolac The risk or severity of adverse effects can be increased when Etodolac is combined with Magnesium salicylate. Approved, Investigational, Vet Approved Etofenamate The risk or severity of adverse effects can be increased when Etofenamate is combined with Magnesium salicylate. Approved, Investigational Etoperidone Etoperidone may increase the antiplatelet activities of Magnesium salicylate. Withdrawn Etoricoxib The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Etoricoxib. Approved, Investigational Evening primrose oil The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Magnesium salicylate. Investigational, Nutraceutical Exisulind The risk or severity of adverse effects can be increased when Exisulind is combined with Magnesium salicylate. Investigational Felbinac The risk or severity of adverse effects can be increased when Felbinac is combined with Magnesium salicylate. Experimental Felodipine The risk or severity of hypotension and neuromuscular blockade can be increased when Felodipine is combined with Magnesium salicylate. Approved, Investigational Fenbufen The risk or severity of adverse effects can be increased when Fenbufen is combined with Magnesium salicylate. Approved Fendiline The risk or severity of hypotension and neuromuscular blockade can be increased when Fendiline is combined with Magnesium salicylate. Withdrawn Fenoprofen The risk or severity of adverse effects can be increased when Fenoprofen is combined with Magnesium salicylate. Approved Fenprostalene The therapeutic efficacy of Fenprostalene can be decreased when used in combination with Magnesium salicylate. Vet Approved Fentiazac The risk or severity of adverse effects can be increased when Fentiazac is combined with Magnesium salicylate. Experimental Feprazone The risk or severity of adverse effects can be increased when Feprazone is combined with Magnesium salicylate. Experimental Ferulic acid The risk or severity of adverse effects can be increased when Ferulic acid is combined with Magnesium salicylate. Experimental Fimasartan The risk or severity of adverse effects can be increased when Fimasartan is combined with Magnesium salicylate. Approved, Investigational Fish oil The risk or severity of hypotension and neuromuscular blockade can be increased when Fish oil is combined with Magnesium salicylate. Approved, Nutraceutical Fleroxacin The serum concentration of Fleroxacin can be decreased when it is combined with Magnesium salicylate. Approved Floctafenine The risk or severity of adverse effects can be increased when Floctafenine is combined with Magnesium salicylate. Approved, Withdrawn Fluasterone The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fluasterone. Investigational Fludrocortisone The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fludrocortisone. Approved, Investigational Fluindione Magnesium salicylate may increase the anticoagulant activities of Fluindione. Approved, Investigational Flumequine The serum concentration of Flumequine can be decreased when it is combined with Magnesium salicylate. Withdrawn Flumethasone The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Flumethasone. Approved, Vet Approved Flunarizine The risk or severity of hypotension and neuromuscular blockade can be increased when Flunarizine is combined with Magnesium salicylate. Approved Flunisolide The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Flunisolide. Approved, Investigational Flunixin The risk or severity of adverse effects can be increased when Flunixin is combined with Magnesium salicylate. Vet Approved Flunoxaprofen The risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Magnesium salicylate. Experimental Fluocinolone Acetonide The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fluocinolone Acetonide. Approved, Investigational, Vet Approved Fluocinonide The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fluocinonide. Approved, Investigational Fluocortolone The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fluocortolone. Approved, Withdrawn Fluorometholone The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fluorometholone. Approved, Investigational Fluoxetine Fluoxetine may increase the antiplatelet activities of Magnesium salicylate. Approved, Vet Approved Fluprednidene The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fluprednidene. Approved, Withdrawn Fluprednisolone The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fluprednisolone. Approved Fluprostenol The therapeutic efficacy of Fluprostenol can be decreased when used in combination with Magnesium salicylate. Vet Approved Flurandrenolide The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Flurandrenolide. Approved Flurbiprofen The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Magnesium salicylate. Approved, Investigational Fluspirilene The risk or severity of hypotension and neuromuscular blockade can be increased when Fluspirilene is combined with Magnesium salicylate. Approved, Investigational Fluticasone The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fluticasone. Approved, Experimental, Investigational Fluticasone furoate The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fluticasone furoate. Approved Fluticasone propionate The risk or severity of gastrointestinal irritation can be increased when Fluticasone propionate is combined with Magnesium salicylate. Approved Fluvoxamine Fluvoxamine may increase the antiplatelet activities of Magnesium salicylate. Approved, Investigational Folic Acid The therapeutic efficacy of Folic Acid can be decreased when used in combination with Magnesium salicylate. Approved, Nutraceutical, Vet Approved Fondaparinux Magnesium salicylate may increase the anticoagulant activities of Fondaparinux sodium. Approved, Investigational Forasartan The risk or severity of adverse effects can be increased when Forasartan is combined with Magnesium salicylate. Experimental Formestane The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Formestane. Approved, Investigational, Withdrawn Fosinopril The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Magnesium salicylate is combined with Fosinopril. Approved Framycetin Magnesium salicylate may decrease the excretion rate of Framycetin which could result in a higher serum level. Approved Furosemide The therapeutic efficacy of Furosemide can be decreased when used in combination with Magnesium salicylate. Approved, Vet Approved Gabapentin The serum concentration of Gabapentin can be decreased when it is combined with Magnesium salicylate. Approved, Investigational Gabexate Magnesium salicylate may increase the anticoagulant activities of Gabexate. Investigational Gallamine Magnesium salicylate may increase the neuromuscular blocking activities of Gallamine. Experimental Gallamine Triethiodide Magnesium salicylate may increase the neuromuscular blocking activities of Gallamine Triethiodide. Approved Gallopamil The risk or severity of hypotension and neuromuscular blockade can be increased when Gallopamil is combined with Magnesium salicylate. Investigational Garenoxacin The serum concentration of Garenoxacin can be decreased when it is combined with Magnesium salicylate. Investigational Gatifloxacin The serum concentration of Gatifloxacin can be decreased when it is combined with Magnesium salicylate. Approved, Investigational Gemeprost The therapeutic efficacy of Gemeprost can be decreased when used in combination with Magnesium salicylate. Approved, Withdrawn Gemifloxacin The serum concentration of Gemifloxacin can be decreased when it is combined with Magnesium salicylate. Approved, Investigational Geneticin Magnesium salicylate may decrease the excretion rate of Geneticin which could result in a higher serum level. Experimental Genistein Magnesium salicylate may increase the thrombogenic activities of Genistein. Investigational Gentamicin Magnesium salicylate may decrease the excretion rate of Gentamicin which could result in a higher serum level. Approved, Vet Approved GENTAMICIN C1A Magnesium salicylate may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level. Experimental Ginseng The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Ginseng. Approved, Investigational, Nutraceutical Glipizide The protein binding of Glipizide can be decreased when combined with Magnesium salicylate. Approved, Investigational Glyburide The protein binding of Glyburide can be decreased when combined with Magnesium salicylate. Approved Grepafloxacin The serum concentration of Grepafloxacin can be decreased when it is combined with Magnesium salicylate. Approved, Investigational, Withdrawn Guacetisal The risk or severity of adverse effects can be increased when Guacetisal is combined with Magnesium salicylate. Experimental Guanfacine The therapeutic efficacy of Guanfacine can be decreased when used in combination with Magnesium salicylate. Approved, Investigational Halcinonide The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Halcinonide. Approved, Investigational, Withdrawn Haloperidol The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Haloperidol. Approved HE3286 The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with HE3286. Investigational Heparin Magnesium salicylate may increase the anticoagulant activities of Heparin. Approved, Investigational Hexestrol Magnesium salicylate may increase the thrombogenic activities of Hexestrol. Withdrawn Higenamine The risk or severity of adverse effects can be increased when Higenamine is combined with Magnesium salicylate. Investigational Hydralazine Magnesium salicylate may decrease the antihypertensive activities of Hydralazine. Approved Hydrochlorothiazide The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Magnesium salicylate. Approved, Vet Approved Hydrocortisone The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Magnesium salicylate. Approved, Vet Approved Hydrocortisone acetate The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone acetate is combined with Magnesium salicylate. Approved, Vet Approved Hydrocortisone butyrate The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone butyrate is combined with Magnesium salicylate. Approved, Vet Approved Hydroflumethiazide The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Magnesium salicylate. Approved, Investigational Hygromycin B Magnesium salicylate may decrease the excretion rate of Hygromycin B which could result in a higher serum level. Vet Approved Ibandronate The risk or severity of gastrointestinal bleeding can be increased when Magnesium salicylate is combined with Ibandronate. Approved, Investigational Ibuprofen The risk or severity of adverse effects can be increased when Ibuprofen is combined with Magnesium salicylate. Approved Ibuproxam The risk or severity of adverse effects can be increased when Ibuproxam is combined with Magnesium salicylate. Withdrawn Icatibant The risk or severity of adverse effects can be increased when Icatibant is combined with Magnesium salicylate. Approved, Investigational Icosapent The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Icosapent. Approved, Nutraceutical Idraparinux Magnesium salicylate may increase the anticoagulant activities of Idraparinux. Investigational Iloprost The therapeutic efficacy of Iloprost can be decreased when used in combination with Magnesium salicylate. Approved, Investigational Imidapril The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Imidapril. Investigational Imidazole salicylate The risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Magnesium salicylate. Experimental Indalpine Indalpine may increase the antiplatelet activities of Magnesium salicylate. Investigational, Withdrawn Indapamide The therapeutic efficacy of Indapamide can be decreased when used in combination with Magnesium salicylate. Approved Indenolol Magnesium salicylate may decrease the antihypertensive activities of Indenolol. Withdrawn Indobufen The risk or severity of adverse effects can be increased when Indobufen is combined with Magnesium salicylate. Investigational Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Magnesium salicylate. Approved, Investigational Indoprofen The risk or severity of adverse effects can be increased when Indoprofen is combined with Magnesium salicylate. Withdrawn Irbesartan The risk or severity of adverse effects can be increased when Irbesartan is combined with Magnesium salicylate. Approved, Investigational Isepamicin Magnesium salicylate may decrease the excretion rate of Isepamicin which could result in a higher serum level. Experimental Isoxicam The risk or severity of adverse effects can be increased when Isoxicam is combined with Magnesium salicylate. Withdrawn Isradipine The risk or severity of hypotension and neuromuscular blockade can be increased when Isradipine is combined with Magnesium salicylate. Approved, Investigational Istaroxime The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Istaroxime. Investigational Kanamycin Magnesium salicylate may decrease the excretion rate of Kanamycin which could result in a higher serum level. Approved, Investigational, Vet Approved Kebuzone The risk or severity of adverse effects can be increased when Kebuzone is combined with Magnesium salicylate. Experimental Ketoprofen The risk or severity of adverse effects can be increased when Ketoprofen is combined with Magnesium salicylate. Approved, Vet Approved Ketorolac The risk or severity of adverse effects can be increased when Ketorolac is combined with Magnesium salicylate. Approved Labetalol Magnesium salicylate may decrease the antihypertensive activities of Labetalol. Approved Lacidipine The risk or severity of hypotension and neuromuscular blockade can be increased when Lacidipine is combined with Magnesium salicylate. Approved, Investigational Lamotrigine The risk or severity of hypotension and neuromuscular blockade can be increased when Lamotrigine is combined with Magnesium salicylate. Approved, Investigational Landiolol Magnesium salicylate may decrease the antihypertensive activities of Landiolol. Investigational Latanoprost The therapeutic efficacy of Latanoprost can be decreased when used in combination with Magnesium salicylate. Approved, Investigational Latanoprostene Bunod The therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Magnesium salicylate. Approved, Investigational Leflunomide The risk or severity of adverse effects can be increased when Leflunomide is combined with Magnesium salicylate. Approved, Investigational Lepirudin Magnesium salicylate may increase the anticoagulant activities of Lepirudin. Approved Lercanidipine The risk or severity of hypotension and neuromuscular blockade can be increased when Lercanidipine is combined with Magnesium salicylate. Approved, Investigational Letaxaban Magnesium salicylate may increase the anticoagulant activities of Letaxaban. Investigational Levetiracetam The risk or severity of hypotension and neuromuscular blockade can be increased when Levetiracetam is combined with Magnesium salicylate. Approved, Investigational Levobetaxolol Magnesium salicylate may decrease the antihypertensive activities of Levobetaxolol. Approved, Investigational Levobunolol Magnesium salicylate may decrease the antihypertensive activities of Levobunolol. Approved Levofloxacin The serum concentration of Levofloxacin can be decreased when it is combined with Magnesium salicylate. Approved, Investigational Levomilnacipran Levomilnacipran may increase the antiplatelet activities of Magnesium salicylate. Approved, Investigational Levothyroxine The serum concentration of Levothyroxine can be decreased when it is combined with Magnesium salicylate. Approved Lidoflazine The risk or severity of hypotension and neuromuscular blockade can be increased when Lidoflazine is combined with Magnesium salicylate. Experimental Limaprost The therapeutic efficacy of Limaprost can be decreased when used in combination with Magnesium salicylate. Approved, Investigational Lipoic Acid Magnesium salicylate can cause a decrease in the absorption of Lipoic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational, Nutraceutical Lisinopril The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Lisinopril. Approved, Investigational Lisofylline The risk or severity of adverse effects can be increased when Lisofylline is combined with Magnesium salicylate. Investigational Lithium cation The serum concentration of Lithium can be increased when it is combined with Magnesium salicylate. Experimental Lomefloxacin The serum concentration of Lomefloxacin can be decreased when it is combined with Magnesium salicylate. Approved, Investigational Lomerizine The risk or severity of hypotension and neuromuscular blockade can be increased when Lomerizine is combined with Magnesium salicylate. Experimental Lonazolac The risk or severity of adverse effects can be increased when Lonazolac is combined with Magnesium salicylate. Experimental Loperamide The risk or severity of hypotension and neuromuscular blockade can be increased when Loperamide is combined with Magnesium salicylate. Approved Lornoxicam The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Lornoxicam. Approved, Investigational Losartan The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Magnesium salicylate. Approved Loteprednol The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Loteprednol. Approved Loxoprofen The risk or severity of adverse effects can be increased when Loxoprofen is combined with Magnesium salicylate. Approved, Investigational Lubiprostone The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Magnesium salicylate. Approved, Investigational Lumiracoxib The risk or severity of adverse effects can be increased when Lumiracoxib is combined with Magnesium salicylate. Approved, Investigational Luprostiol The therapeutic efficacy of Luprostiol can be decreased when used in combination with Magnesium salicylate. Vet Approved Magnesium sulfate The risk or severity of hypotension and neuromuscular blockade can be increased when Magnesium sulfate is combined with Magnesium salicylate. Approved, Investigational, Vet Approved Manidipine The risk or severity of hypotension and neuromuscular blockade can be increased when Manidipine is combined with Magnesium salicylate. Approved, Investigational Masoprocol The risk or severity of adverse effects can be increased when Masoprocol is combined with Magnesium salicylate. Approved, Investigational ME-609 The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with ME-609. Investigational Meclofenamic acid The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Magnesium salicylate. Approved, Vet Approved Medrysone The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Medrysone. Approved Mefenamic acid The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Magnesium salicylate. Approved Melagatran Magnesium salicylate may increase the anticoagulant activities of Melagatran. Experimental Melengestrol The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Melengestrol. Vet Approved Meloxicam The risk or severity of adverse effects can be increased when Meloxicam is combined with Magnesium salicylate. Approved, Vet Approved Menthol The risk or severity of hypotension and neuromuscular blockade can be increased when Menthol is combined with Magnesium salicylate. Approved Mepindolol Magnesium salicylate may decrease the antihypertensive activities of Mepindolol. Experimental Mesalazine The risk or severity of adverse effects can be increased when Mesalazine is combined with Magnesium salicylate. Approved Mestranol Magnesium salicylate may increase the thrombogenic activities of Mestranol. Approved Metamizole The risk or severity of adverse effects can be increased when Metamizole is combined with Magnesium salicylate. Approved, Investigational, Withdrawn Methallenestril Magnesium salicylate may increase the thrombogenic activities of Methallenestril. Experimental Methotrexate The serum concentration of Methotrexate can be increased when it is combined with Magnesium salicylate. Approved Methsuximide The risk or severity of hypotension and neuromuscular blockade can be increased when Methsuximide is combined with Magnesium salicylate. Approved Methyclothiazide The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Magnesium salicylate. Approved Methyl salicylate The therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Magnesium salicylate. Approved, Vet Approved Methylprednisolone The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Magnesium salicylate. Approved, Vet Approved Metipranolol Magnesium salicylate may decrease the antihypertensive activities of Metipranolol. Approved Metocurine Magnesium salicylate may increase the neuromuscular blocking activities of Metocurine. Approved Metocurine Iodide Magnesium salicylate may increase the neuromuscular blocking activities of Metocurine Iodide. Approved, Withdrawn Metolazone The therapeutic efficacy of Metolazone can be decreased when used in combination with Magnesium salicylate. Approved Metoprolol Magnesium salicylate may decrease the antihypertensive activities of Metoprolol. Approved, Investigational Mibefradil The risk or severity of hypotension and neuromuscular blockade can be increased when Mibefradil is combined with Magnesium salicylate. Investigational, Withdrawn Micronomicin Magnesium salicylate may decrease the excretion rate of Micronomicin which could result in a higher serum level. Experimental Mifamurtide The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Magnesium salicylate. Approved, Experimental Milnacipran Milnacipran may increase the antiplatelet activities of Magnesium salicylate. Approved, Investigational Minocycline Magnesium salicylate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Minoxidil The therapeutic efficacy of Minoxidil can be decreased when used in combination with Magnesium salicylate. Approved, Investigational Misoprostol The therapeutic efficacy of Misoprostol can be decreased when used in combination with Magnesium salicylate. Approved Mivacurium Magnesium salicylate may increase the neuromuscular blocking activities of Mivacurium. Approved Mizoribine The risk or severity of adverse effects can be increased when Mizoribine is combined with Magnesium salicylate. Investigational Moexipril The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Moexipril. Approved Mofebutazone The risk or severity of adverse effects can be increased when Mofebutazone is combined with Magnesium salicylate. Experimental Mometasone The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Mometasone. Approved, Vet Approved Morniflumate The risk or severity of adverse effects can be increased when Morniflumate is combined with Magnesium salicylate. Approved Moxestrol Magnesium salicylate may increase the thrombogenic activities of Moxestrol. Experimental Moxifloxacin Magnesium salicylate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Magnesium salicylate. Approved, Investigational Mycophenolic acid The serum concentration of Mycophenolic acid can be decreased when it is combined with Magnesium salicylate. Approved Nabumetone The risk or severity of adverse effects can be increased when Nabumetone is combined with Magnesium salicylate. Approved Nadolol Magnesium salicylate may decrease the antihypertensive activities of Nadolol. Approved Nadroparin Magnesium salicylate may increase the anticoagulant activities of Nadroparin. Approved, Investigational Nafamostat The risk or severity of adverse effects can be increased when Nafamostat is combined with Magnesium salicylate. Approved, Investigational Naftifine The risk or severity of adverse effects can be increased when Naftifine is combined with Magnesium salicylate. Approved Naftopidil The risk or severity of hypotension and neuromuscular blockade can be increased when Naftopidil is combined with Magnesium salicylate. Investigational Nalidixic Acid The serum concentration of Nalidixic Acid can be decreased when it is combined with Magnesium salicylate. Approved, Investigational Naproxen The risk or severity of adverse effects can be increased when Naproxen is combined with Magnesium salicylate. Approved, Vet Approved NCX 1022 The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with NCX 1022. Investigational Neamine Magnesium salicylate may decrease the excretion rate of Neamine which could result in a higher serum level. Experimental Nebivolol Magnesium salicylate may decrease the antihypertensive activities of Nebivolol. Approved, Investigational Nefazodone Nefazodone may increase the antiplatelet activities of Magnesium salicylate. Approved, Withdrawn Nemonoxacin The serum concentration of Nemonoxacin can be decreased when it is combined with Magnesium salicylate. Investigational Neomycin The risk or severity of nephrotoxicity can be increased when Magnesium salicylate is combined with Neomycin. Approved, Vet Approved Neosaxitoxin Magnesium salicylate may increase the neuromuscular blocking activities of Neosaxitoxin. Investigational Nepafenac The risk or severity of adverse effects can be increased when Nepafenac is combined with Magnesium salicylate. Approved, Investigational Netilmicin Magnesium salicylate may decrease the excretion rate of Netilmicin which could result in a higher serum level. Approved, Investigational Nicardipine The risk or severity of hypotension and neuromuscular blockade can be increased when Nicardipine is combined with Magnesium salicylate. Approved, Investigational Nifedipine The risk or severity of hypotension and neuromuscular blockade can be increased when Nifedipine is combined with Magnesium salicylate. Approved Nifenazone The risk or severity of adverse effects can be increased when Nifenazone is combined with Magnesium salicylate. Experimental Niflumic Acid The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Niflumic Acid. Approved Niguldipine The risk or severity of hypotension and neuromuscular blockade can be increased when Niguldipine is combined with Magnesium salicylate. Experimental Niludipine The risk or severity of hypotension and neuromuscular blockade can be increased when Niludipine is combined with Magnesium salicylate. Experimental Nilvadipine The risk or severity of hypotension and neuromuscular blockade can be increased when Nilvadipine is combined with Magnesium salicylate. Approved, Investigational Nimesulide The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Nimesulide. Approved, Investigational, Withdrawn Nimodipine The risk or severity of hypotension and neuromuscular blockade can be increased when Nimodipine is combined with Magnesium salicylate. Approved, Investigational Nisoldipine The risk or severity of hypotension and neuromuscular blockade can be increased when Nisoldipine is combined with Magnesium salicylate. Approved Nitrendipine The risk or severity of hypotension and neuromuscular blockade can be increased when Nitrendipine is combined with Magnesium salicylate. Approved, Investigational Nitroaspirin The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Magnesium salicylate. Investigational Norfloxacin The serum concentration of Norfloxacin can be decreased when it is combined with Magnesium salicylate. Approved Nylidrin The risk or severity of hypotension and neuromuscular blockade can be increased when Nylidrin is combined with Magnesium salicylate. Approved Ofloxacin The serum concentration of Ofloxacin can be decreased when it is combined with Magnesium salicylate. Approved Oleoyl-estrone The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Oleoyl-estrone. Investigational Olmesartan The risk or severity of adverse effects can be increased when Olmesartan is combined with Magnesium salicylate. Approved, Investigational Olopatadine The risk or severity of adverse effects can be increased when Olopatadine is combined with Magnesium salicylate. Approved Olsalazine The risk or severity of adverse effects can be increased when Olsalazine is combined with Magnesium salicylate. Approved Omacetaxine mepesuccinate The risk or severity of bleeding can be increased when Magnesium salicylate is combined with Omacetaxine mepesuccinate. Approved, Investigational Omapatrilat The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Omapatrilat. Investigational Orgotein The risk or severity of adverse effects can be increased when Orgotein is combined with Magnesium salicylate. Vet Approved Otamixaban Magnesium salicylate may increase the anticoagulant activities of Otamixaban. Investigational Otilonium The risk or severity of hypotension and neuromuscular blockade can be increased when Otilonium is combined with Magnesium salicylate. Experimental, Investigational Oxaprozin The risk or severity of adverse effects can be increased when Oxaprozin is combined with Magnesium salicylate. Approved Oxolinic acid The serum concentration of Oxolinic acid can be decreased when it is combined with Magnesium salicylate. Experimental Oxprenolol Magnesium salicylate may decrease the antihypertensive activities of Oxprenolol. Approved Oxyphenbutazone The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Magnesium salicylate. Approved, Withdrawn Oxytetracycline Magnesium salicylate can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational, Vet Approved Palmidrol The risk or severity of adverse effects can be increased when Palmidrol is combined with Magnesium salicylate. Experimental, Nutraceutical Pamidronate The serum concentration of Pamidronate can be decreased when it is combined with Magnesium salicylate. Approved Pancuronium Magnesium salicylate may increase the neuromuscular blocking activities of Pancuronium. Approved Paramethasone The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Paramethasone. Approved Parecoxib The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Parecoxib. Approved Paromomycin The risk or severity of nephrotoxicity can be increased when Magnesium salicylate is combined with Paromomycin. Approved, Investigational Paroxetine Paroxetine may increase the antiplatelet activities of Magnesium salicylate. Approved, Investigational Parthenolide The risk or severity of adverse effects can be increased when Parthenolide is combined with Magnesium salicylate. Approved, Investigational Pazufloxacin The serum concentration of Pazufloxacin can be decreased when it is combined with Magnesium salicylate. Investigational Pefloxacin The serum concentration of Pefloxacin can be decreased when it is combined with Magnesium salicylate. Approved Penbutolol Magnesium salicylate may decrease the antihypertensive activities of Penbutolol. Approved, Investigational Penfluridol The risk or severity of hypotension and neuromuscular blockade can be increased when Penfluridol is combined with Magnesium salicylate. Experimental Pentaerythritol Tetranitrate Magnesium salicylate may increase the anticoagulant activities of Pentaerythritol Tetranitrate. Approved Pentosan Polysulfate Magnesium salicylate may increase the anticoagulant activities of Pentosan Polysulfate. Approved Perindopril The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Perindopril. Approved Phenindione Magnesium salicylate may increase the anticoagulant activities of Phenindione. Approved, Investigational Phenprocoumon Magnesium salicylate may increase the anticoagulant activities of Phenprocoumon. Approved, Investigational Phenylbutazone The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Magnesium salicylate. Approved, Vet Approved Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Magnesium salicylate. Approved, Investigational Pinaverium The risk or severity of hypotension and neuromuscular blockade can be increased when Pinaverium is combined with Magnesium salicylate. Approved Pindolol Magnesium salicylate may decrease the antihypertensive activities of Pindolol. Approved, Investigational Pipecuronium Magnesium salicylate may increase the neuromuscular blocking activities of Pipecuronium. Approved Pipemidic acid The serum concentration of Pipemidic acid can be decreased when it is combined with Magnesium salicylate. Experimental Piretanide The therapeutic efficacy of Piretanide can be decreased when used in combination with Magnesium salicylate. Approved Pirfenidone The risk or severity of adverse effects can be increased when Pirfenidone is combined with Magnesium salicylate. Approved, Investigational Piromidic acid The serum concentration of Piromidic acid can be decreased when it is combined with Magnesium salicylate. Experimental Piroxicam The risk or severity of adverse effects can be increased when Piroxicam is combined with Magnesium salicylate. Approved, Investigational Pirprofen The risk or severity of adverse effects can be increased when Pirprofen is combined with Magnesium salicylate. Experimental Pitolisant The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Pitolisant. Approved, Investigational Platelet Activating Factor Magnesium salicylate may decrease the antihypertensive activities of Platelet Activating Factor. Experimental Plazomicin Magnesium salicylate may decrease the excretion rate of Plazomicin which could result in a higher serum level. Approved, Investigational Polyestradiol phosphate Magnesium salicylate may increase the thrombogenic activities of Polyestradiol phosphate. Approved Polythiazide The therapeutic efficacy of Polythiazide can be decreased when used in combination with Magnesium salicylate. Approved Pomalidomide The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Pomalidomide. Approved Potassium Citrate Magnesium salicylate may increase the anticoagulant activities of Potassium Citrate. Approved, Investigational, Vet Approved Practolol Magnesium salicylate may decrease the antihypertensive activities of Practolol. Approved Pralatrexate The serum concentration of Pralatrexate can be increased when it is combined with Magnesium salicylate. Approved, Investigational Pranoprofen The risk or severity of adverse effects can be increased when Pranoprofen is combined with Magnesium salicylate. Experimental, Investigational Prasterone The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Prasterone. Approved, Investigational, Nutraceutical Prasterone sulfate The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Prasterone sulfate. Investigational Prednicarbate The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Prednicarbate. Approved, Investigational Prednisolone The risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Magnesium salicylate. Approved, Vet Approved Prednisone The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Prednisone. Approved, Vet Approved Pregnenolone The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Pregnenolone. Approved, Experimental, Investigational Prenylamine The risk or severity of hypotension and neuromuscular blockade can be increased when Prenylamine is combined with Magnesium salicylate. Withdrawn Probenecid The serum concentration of Magnesium salicylate can be increased when it is combined with Probenecid. Approved, Investigational Proglumetacin The risk or severity of adverse effects can be increased when Proglumetacin is combined with Magnesium salicylate. Experimental Promestriene Magnesium salicylate may increase the thrombogenic activities of Promestriene. Investigational Propacetamol The risk or severity of adverse effects can be increased when Propacetamol is combined with Magnesium salicylate. Approved, Investigational Propafenone Magnesium salicylate may decrease the antihypertensive activities of Propafenone. Approved Propranolol Magnesium salicylate may decrease the antihypertensive activities of Propranolol. Approved, Investigational Propyphenazone The risk or severity of adverse effects can be increased when Propyphenazone is combined with Magnesium salicylate. Experimental Proquazone The risk or severity of adverse effects can be increased when Proquazone is combined with Magnesium salicylate. Experimental Prostaglandin B2 The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Magnesium salicylate. Experimental Prostaglandin G2 The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Magnesium salicylate. Experimental Prostalene The therapeutic efficacy of Prostalene can be decreased when used in combination with Magnesium salicylate. Vet Approved Protein C Magnesium salicylate may increase the anticoagulant activities of Protein C. Approved Protein S human Magnesium salicylate may increase the anticoagulant activities of Protein S human. Approved Protocatechualdehyde Magnesium salicylate may increase the anticoagulant activities of Protocatechualdehyde. Approved Prulifloxacin The serum concentration of Prulifloxacin can be decreased when it is combined with Magnesium salicylate. Investigational PTC299 The risk or severity of adverse effects can be increased when PTC299 is combined with Magnesium salicylate. Investigational Puromycin Magnesium salicylate may decrease the excretion rate of Puromycin which could result in a higher serum level. Experimental Quinapril The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Quinapril. Approved, Investigational Quinestrol Magnesium salicylate may increase the thrombogenic activities of Quinestrol. Approved Quinethazone The therapeutic efficacy of Quinethazone can be decreased when used in combination with Magnesium salicylate. Approved Raltegravir The serum concentration of Raltegravir can be decreased when it is combined with Magnesium salicylate. Approved Ramipril The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Ramipril. Approved Rapacuronium Magnesium salicylate may increase the neuromuscular blocking activities of Rapacuronium. Withdrawn Rescinnamine The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Rescinnamine. Approved Resveratrol The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Resveratrol. Approved, Experimental, Investigational Reviparin Magnesium salicylate may increase the anticoagulant activities of Reviparin. Approved, Investigational Ribostamycin Magnesium salicylate may decrease the excretion rate of Ribostamycin which could result in a higher serum level. Approved, Investigational Rimexolone The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Rimexolone. Approved Risedronate The serum concentration of Risedronate can be decreased when it is combined with Magnesium salicylate. Approved, Investigational Rivaroxaban Magnesium salicylate may increase the anticoagulant activities of Rivaroxaban. Approved Rocuronium Magnesium salicylate may increase the neuromuscular blocking activities of Rocuronium. Approved Rofecoxib The risk or severity of adverse effects can be increased when Rofecoxib is combined with Magnesium salicylate. Approved, Investigational, Withdrawn Rosoxacin The serum concentration of Rosoxacin can be decreased when it is combined with Magnesium salicylate. Approved, Investigational Rufloxacin The serum concentration of Rufloxacin can be decreased when it is combined with Magnesium salicylate. Experimental Sacubitril The risk or severity of adverse effects can be increased when Sacubitril is combined with Magnesium salicylate. Approved Salicylamide The risk or severity of adverse effects can be increased when Salicylamide is combined with Magnesium salicylate. Approved Salicylic acid The risk or severity of adverse effects can be increased when Salicylic acid is combined with Magnesium salicylate. Approved, Investigational, Vet Approved Salsalate The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Salsalate. Approved Saprisartan The risk or severity of adverse effects can be increased when Saprisartan is combined with Magnesium salicylate. Experimental Saralasin The risk or severity of adverse effects can be increased when Saralasin is combined with Magnesium salicylate. Investigational Sarilumab Sarilumab may increase the immunosuppressive activities of Magnesium salicylate. Approved, Investigational Secoisolariciresinol Magnesium salicylate may increase the thrombogenic activities of Secoisolariciresinol. Investigational Seletracetam The risk or severity of hypotension and neuromuscular blockade can be increased when Seletracetam is combined with Magnesium salicylate. Investigational Seliciclib The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Seliciclib. Investigational Semapimod The risk or severity of adverse effects can be increased when Semapimod is combined with Magnesium salicylate. Investigational Seratrodast The risk or severity of adverse effects can be increased when Seratrodast is combined with Magnesium salicylate. Approved Serrapeptase The risk or severity of adverse effects can be increased when Serrapeptase is combined with Magnesium salicylate. Investigational Sertraline Sertraline may increase the antiplatelet activities of Magnesium salicylate. Approved Sisomicin Magnesium salicylate may decrease the excretion rate of Sisomicin which could result in a higher serum level. Investigational Sitafloxacin The serum concentration of Sitafloxacin can be decreased when it is combined with Magnesium salicylate. Experimental, Investigational Sodium Citrate The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Sodium Citrate. Approved, Investigational Sodium glycerophosphate The serum concentration of Sodium glycerophosphate can be decreased when it is combined with Magnesium salicylate. Approved Sodium phosphate, monobasic The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Magnesium salicylate. Approved Sotalol Magnesium salicylate may decrease the antihypertensive activities of Sotalol. Approved Sparfloxacin The serum concentration of Sparfloxacin can be decreased when it is combined with Magnesium salicylate. Approved, Investigational Spirapril The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Spirapril. Approved Spironolactone The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Magnesium salicylate is combined with Spironolactone. Approved SRT501 The risk or severity of adverse effects can be increased when SRT501 is combined with Magnesium salicylate. Investigational Streptomycin Magnesium salicylate may decrease the excretion rate of Streptomycin which could result in a higher serum level. Approved, Vet Approved Succinylcholine Magnesium salicylate may increase the neuromuscular blocking activities of Succinylcholine. Approved Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Magnesium salicylate. Approved Sulindac The risk or severity of adverse effects can be increased when Sulindac is combined with Magnesium salicylate. Approved, Investigational Sulodexide Magnesium salicylate may increase the anticoagulant activities of Sulodexide. Approved, Investigational Sulprostone The therapeutic efficacy of Sulprostone can be decreased when used in combination with Magnesium salicylate. Investigational Suprofen The risk or severity of adverse effects can be increased when Suprofen is combined with Magnesium salicylate. Approved, Withdrawn Suxibuzone The risk or severity of adverse effects can be increased when Suxibuzone is combined with Magnesium salicylate. Experimental Synthetic Conjugated Estrogens, A Magnesium salicylate may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A. Approved Synthetic Conjugated Estrogens, B Magnesium salicylate may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B. Approved Tacrolimus Magnesium salicylate may increase the nephrotoxic activities of Tacrolimus. Approved, Investigational Tafluprost The therapeutic efficacy of Tafluprost can be decreased when used in combination with Magnesium salicylate. Approved Talinolol Magnesium salicylate may decrease the antihypertensive activities of Talinolol. Investigational Talniflumate The risk or severity of adverse effects can be increased when Talniflumate is combined with Magnesium salicylate. Approved Tarenflurbil The risk or severity of adverse effects can be increased when Tarenflurbil is combined with Magnesium salicylate. Investigational Tasosartan The risk or severity of adverse effects can be increased when Tasosartan is combined with Magnesium salicylate. Approved Technetium Tc-99m etidronate The serum concentration of Technetium Tc-99m etidronate can be decreased when it is combined with Magnesium salicylate. Approved Technetium Tc-99m medronate The serum concentration of Technetium Tc-99m medronate can be decreased when it is combined with Magnesium salicylate. Approved Telmisartan The risk or severity of adverse effects can be increased when Telmisartan is combined with Magnesium salicylate. Approved, Investigational Temafloxacin The serum concentration of Temafloxacin can be decreased when it is combined with Magnesium salicylate. Withdrawn Temocapril The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Temocapril. Experimental, Investigational Tenidap The risk or severity of adverse effects can be increased when Tenidap is combined with Magnesium salicylate. Experimental Tenofovir disoproxil The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Tenofovir disoproxil. Approved, Investigational Tenoxicam The risk or severity of adverse effects can be increased when Tenoxicam is combined with Magnesium salicylate. Approved Tepoxalin The risk or severity of adverse effects can be increased when Tepoxalin is combined with Magnesium salicylate. Vet Approved Terbutaline Magnesium salicylate may decrease the antihypertensive activities of Terbutaline. Approved Teriflunomide The risk or severity of adverse effects can be increased when Teriflunomide is combined with Magnesium salicylate. Approved Terodiline The risk or severity of hypotension and neuromuscular blockade can be increased when Terodiline is combined with Magnesium salicylate. Experimental Tertatolol Magnesium salicylate may decrease the antihypertensive activities of Tertatolol. Experimental Tetracycline Magnesium salicylate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Vet Approved Tetrahydropalmatine The risk or severity of hypotension and neuromuscular blockade can be increased when Tetrahydropalmatine is combined with Magnesium salicylate. Investigational Tetrandrine The risk or severity of hypotension and neuromuscular blockade can be increased when Tetrandrine is combined with Magnesium salicylate. Experimental Tiaprofenic acid The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Tiaprofenic acid. Approved Tibolone Magnesium salicylate may increase the thrombogenic activities of Tibolone. Approved, Investigational Tiludronic acid The serum concentration of Tiludronic acid can be decreased when it is combined with Magnesium salicylate. Approved, Investigational, Vet Approved Timolol Magnesium salicylate may decrease the antihypertensive activities of Timolol. Approved Tinoridine The risk or severity of adverse effects can be increased when Tinoridine is combined with Magnesium salicylate. Investigational Tioclomarol Magnesium salicylate may increase the anticoagulant activities of Tioclomarol. Experimental Tixocortol The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Tixocortol. Approved, Withdrawn Tobramycin Magnesium salicylate may decrease the excretion rate of Tobramycin which could result in a higher serum level. Approved, Investigational Tolfenamic Acid The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Tolfenamic Acid. Approved, Investigational Tolmetin The risk or severity of adverse effects can be increased when Tolmetin is combined with Magnesium salicylate. Approved Torasemide The therapeutic efficacy of Torasemide can be decreased when used in combination with Magnesium salicylate. Approved Trandolapril The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Trandolapril. Approved Tranilast The risk or severity of hypotension and neuromuscular blockade can be increased when Tranilast is combined with Magnesium salicylate. Approved, Investigational Travoprost The therapeutic efficacy of Travoprost can be decreased when used in combination with Magnesium salicylate. Approved Treprostinil The risk or severity of adverse effects can be increased when Treprostinil is combined with Magnesium salicylate. Approved, Investigational Triamcinolone The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Triamcinolone. Approved, Vet Approved Triamterene Magnesium salicylate may decrease the antihypertensive activities of Triamterene. Approved Tribenoside The risk or severity of adverse effects can be increased when Tribenoside is combined with Magnesium salicylate. Experimental Trichlormethiazide The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Magnesium salicylate. Approved, Vet Approved Triethylenetetramine The serum concentration of Magnesium salicylate can be decreased when it is combined with Triethylenetetramine. Approved, Investigational Trimebutine The risk or severity of hypotension and neuromuscular blockade can be increased when Trimebutine is combined with Magnesium salicylate. Approved Trimethadione The risk or severity of hypotension and neuromuscular blockade can be increased when Trimethadione is combined with Magnesium salicylate. Approved Triptolide The risk or severity of adverse effects can be increased when Triptolide is combined with Magnesium salicylate. Investigational Trolamine salicylate The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Trolamine salicylate. Approved Trovafloxacin The serum concentration of Trovafloxacin can be decreased when it is combined with Magnesium salicylate. Approved, Investigational, Withdrawn Troxerutin Magnesium salicylate may increase the anticoagulant activities of Troxerutin. Investigational Tubocurarine Magnesium salicylate may increase the neuromuscular blocking activities of Tubocurarine. Approved Ulobetasol The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Ulobetasol. Approved Unoprostone The therapeutic efficacy of Unoprostone can be decreased when used in combination with Magnesium salicylate. Approved, Investigational Valdecoxib The risk or severity of adverse effects can be increased when Valdecoxib is combined with Magnesium salicylate. Approved, Investigational, Withdrawn Valsartan The risk or severity of adverse effects can be increased when Valsartan is combined with Magnesium salicylate. Approved, Investigational Vancomycin Magnesium salicylate may decrease the excretion rate of Vancomycin which could result in a higher serum level. Approved Venlafaxine Venlafaxine may increase the antiplatelet activities of Magnesium salicylate. Approved Verapamil The risk or severity of hypotension and neuromuscular blockade can be increased when Verapamil is combined with Magnesium salicylate. Approved Vinpocetine The risk or severity of hypotension and neuromuscular blockade can be increased when Vinpocetine is combined with Magnesium salicylate. Investigational Warfarin Magnesium salicylate may increase the anticoagulant activities of Warfarin. Approved WIN 55212-2 The risk or severity of hypotension and neuromuscular blockade can be increased when WIN 55212-2 is combined with Magnesium salicylate. Experimental Ximelagatran Magnesium salicylate may increase the anticoagulant activities of Ximelagatran. Approved, Investigational, Withdrawn Zaltoprofen The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Magnesium salicylate. Approved, Investigational Zeranol Magnesium salicylate may increase the thrombogenic activities of Zeranol. Vet Approved Ziconotide The risk or severity of hypotension and neuromuscular blockade can be increased when Ziconotide is combined with Magnesium salicylate. Approved Zileuton The risk or severity of adverse effects can be increased when Zileuton is combined with Magnesium salicylate. Approved, Investigational, Withdrawn Zimelidine Zimelidine may increase the antiplatelet activities of Magnesium salicylate. Withdrawn Zofenopril The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Zofenopril. Experimental Zoledronic acid The risk or severity of gastrointestinal bleeding can be increased when Magnesium salicylate is combined with Zoledronic acid. Approved Zomepirac The risk or severity of adverse effects can be increased when Zomepirac is combined with Magnesium salicylate. Withdrawn Zonisamide The risk or severity of hypotension and neuromuscular blockade can be increased when Zonisamide is combined with Magnesium salicylate. Approved, Investigational - Food Interactions
- Not Available
References
- Synthesis Reference
Satishchandra P. Patel, Vinayak T. Bhalani, "Solid choline magnesium salicylate composition and method of preparing same." U.S. Patent US5043168, issued May, 1954.
US5043168- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0015469
- KEGG Compound
- C07995
- PubChem Compound
- 54684589
- PubChem Substance
- 46508713
- ChemSpider
- 58278
- ChEBI
- 6640
- ChEMBL
- CHEMBL2106755
- PharmGKB
- PA450300
- Wikipedia
- Magnesium_salicylate
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Caraco Pharmaceutical Labs
- CVS Pharmacy
- Ivax Pharmaceuticals
- Key Co.
- Novartis AG
- Palmetto Pharmaceuticals Inc.
- Qualitest
- US Pharmaceutical Corp.
- Dosage forms
Form Route Strength Tablet Oral 325 mg Tablet, film coated Oral 580 mg/1 Tablet, coated Oral Tablet Oral 580 mg/1 Capsule Oral 580 mg/1 Tablet Oral 650 mg Tablet, film coated Oral Tablet Oral Tablet, coated Oral 467 mg/1 - Prices
Unit description Cost Unit Tricosal 1000 mg tablet 1.23USD tablet Choline mag trisal 1 gm tablet 1.15USD tablet Choline mag trisal 750 mg tablet 0.81USD tablet Novasal 600 mg tablet 0.75USD tablet Choline mag trisal 500 mg tablet 0.64USD tablet Doan's ex strength 580 mg tablet 0.22USD tablet CVS Pharmacy backache rlf 580 mg caplet 0.18USD caplet Doan's regular 325 mg tablet 0.18USD tablet Keygesic-10 650 mg tablet 0.05USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0686 mg/mL ALOGPS logP 2.86 ALOGPS logP 1.98 ChemAxon logS -3.6 ALOGPS pKa (Strongest Acidic) 2.79 ChemAxon pKa (Strongest Basic) -6.3 ChemAxon Physiological Charge -1 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 60.36 Å2 ChemAxon Rotatable Bond Count 2 ChemAxon Refractivity 46.13 m3·mol-1 ChemAxon Polarizability 12.38 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.5741 Blood Brain Barrier + 0.829 Caco-2 permeable + 0.5941 P-glycoprotein substrate Non-substrate 0.6758 P-glycoprotein inhibitor I Non-inhibitor 0.9704 P-glycoprotein inhibitor II Non-inhibitor 0.9768 Renal organic cation transporter Non-inhibitor 0.8975 CYP450 2C9 substrate Non-substrate 0.7872 CYP450 2D6 substrate Non-substrate 0.9101 CYP450 3A4 substrate Non-substrate 0.7282 CYP450 1A2 substrate Non-inhibitor 0.8837 CYP450 2C9 inhibitor Non-inhibitor 0.5705 CYP450 2D6 inhibitor Non-inhibitor 0.9113 CYP450 2C19 inhibitor Non-inhibitor 0.8537 CYP450 3A4 inhibitor Non-inhibitor 0.9421 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9021 Ames test Non AMES toxic 0.9695 Carcinogenicity Non-carcinogens 0.8587 Biodegradation Ready biodegradable 0.8277 Rat acute toxicity 2.3552 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.952 hERG inhibition (predictor II) Non-inhibitor 0.9555
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as salicylic acids. These are ortho-hydroxylated benzoic acids.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Benzoic acids and derivatives
- Direct Parent
- Salicylic acids
- Alternative Parents
- Benzoic acids / Benzoyl derivatives / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Vinylogous acids / Carboxylic acid salts / Monocarboxylic acids and derivatives / Carboxylic acids / Organooxygen compounds / Organic salts show 2 more
- Substituents
- Salicylic acid / Benzoic acid / Benzoyl / 1-hydroxy-4-unsubstituted benzenoid / 1-hydroxy-2-unsubstituted benzenoid / Phenol / Vinylogous acid / Carboxylic acid salt / Monocarboxylic acid or derivatives / Carboxylic acid show 7 more
- Molecular Framework
- Not Available
- External Descriptors
- benzenes, carbonyl compound (CHEBI:6640)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Prostaglandin-endoperoxide synthase activity
- Specific Function
- Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
- Gene Name
- PTGS2
- Uniprot ID
- P35354
- Uniprot Name
- Prostaglandin G/H synthase 2
- Molecular Weight
- 68995.625 Da
References
- Graham GG, Scott KF: Mechanisms of action of paracetamol and related analgesics. Inflammopharmacology. 2003;11(4):401-13. [PubMed:15035793]
- Fiebich BL, Chrubasik S: Effects of an ethanolic salix extract on the release of selected inflammatory mediators in vitro. Phytomedicine. 2004 Feb;11(2-3):135-8. [PubMed:15070163]
- Chae HJ, Chae SW, Reed JC, Kim HR: Salicylate regulates COX-2 expression through ERK and subsequent NF-kappaB activation in osteoblasts. Immunopharmacol Immunotoxicol. 2004 Feb;26(1):75-91. [PubMed:15106733]
- Wu KK: Aspirin and other cyclooxygenase inhibitors: new therapeutic insights. Semin Vasc Med. 2003 May;3(2):107-12. [PubMed:15199473]
- Elvira C, Gallardo A, Lacroix N, Schacht E, San Roman J: Incorporation of salicylic acid derivatives to hydrophilic copolymer systems with biomedical applications. J Mater Sci Mater Med. 2001 Jun;12(6):535-42. [PubMed:15348270]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Prostaglandin-endoperoxide synthase activity
- Specific Function
- Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
- Gene Name
- PTGS1
- Uniprot ID
- P23219
- Uniprot Name
- Prostaglandin G/H synthase 1
- Molecular Weight
- 68685.82 Da
References
- Moon C, Ahn M, Jee Y, Heo S, Kim S, Kim H, Sim KB, Koh CS, Shin YG, Shin T: Sodium salicylate-induced amelioration of experimental autoimmune encephalomyelitis in Lewis rats is associated with the suppression of inducible nitric oxide synthase and cyclooxygenases. Neurosci Lett. 2004 Feb 12;356(2):123-6. [PubMed:14746879]
- Graham GG, Scott KF: Mechanisms of action of paracetamol and related analgesics. Inflammopharmacology. 2003;11(4):401-13. [PubMed:15035793]
- Sun R, Carlson NG, Hemmert AC, Kishore BK: P2Y2 receptor-mediated release of prostaglandin E2 by IMCD is altered in hydrated and dehydrated rats: relevance to AVP-independent regulation of IMCD function. Am J Physiol Renal Physiol. 2005 Sep;289(3):F585-92. Epub 2005 Apr 19. [PubMed:15840771]
- Celik G, Pasaoglu G, Bavbek S, Abadoglu O, Dursun B, Mungan D, Misirligil Z: Tolerability of selective cyclooxygenase inhibitor, celecoxib, in patients with analgesic intolerance. J Asthma. 2005 Mar;42(2):127-31. [PubMed:15871445]
- Liu X, Lee TL, Wong PT: Cyclooxygenase-1 inhibition shortens the duration of diazepam-induced loss of righting reflex in mice. Anesth Analg. 2006 Jan;102(1):135-40. [PubMed:16368818]
Carriers
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- No
- General Function
- Toxic substance binding
- Specific Function
- Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
- Gene Name
- ALB
- Uniprot ID
- P02768
- Uniprot Name
- Serum albumin
- Molecular Weight
- 69365.94 Da
References
- Zhang Q, Huang Y, Zhao R, Liu G, Chen Y: Determining binding sites of drugs on human serum albumin using FIA-QCM. Biosens Bioelectron. 2008 Sep 15;24(1):48-54. doi: 10.1016/j.bios.2008.03.009. Epub 2008 Mar 21. [PubMed:18436441]
Drug created on July 08, 2007 11:04 / Updated on August 02, 2018 07:59